Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AmgenCHIX:AMGD 89 3-Year EPS without NRI Growth Rate is 7.30% as of Mar. 2026, which is 55% below its 10-year median of 16.10. GuruFocus rates CHIX:AMGD with a GF Score™ of 89/100 and a GF Value™ of €326.28 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 788 Drug Manufacturers companies, Amgen ranks worse than 53.81% on this metric.
During the past 12 months, Amgen's average EPS without NRI Growth Rate was 6.50% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 7.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 5.50% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 7.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Amgen was 165.30% per year. The lowest was -33.10% per year. And the median was 16.10% per year.
Amgen (CHIX:AMGd) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Amgen 3-Year EPS without NRI Growth Rate Related Terms
CHIX:AMGD vs GILD, PFE, BMY: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Amgen's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Amgen's 3-Year EPS without NRI Growth Rate falls into.
Amgen 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 7.30% mean?
Amgen (CHIX:AMGD) has a 3-Year EPS without NRI Growth Rate of 7.30% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Amgen and its competitors. This is 55% below median its historical median of 16.10. According to the industry distribution chart, Amgen ranks #424 out of 788 companies in the Drug Manufacturers industry, placing it in the top 53.8%.
Is Amgen's 3-Year EPS without NRI Growth Rate too high?
Amgen's current 3-Year EPS without NRI Growth Rate of 7.30% is 55% below median its 10-year median of 16.10. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.60. Amgen's value of 7.30% is 24% below this industry median. Based on the distribution chart, Amgen ranks #424 out of 788 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amgen has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's 3-Year EPS without NRI Growth Rate compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #424 out of 788 companies for 3-Year EPS without NRI Growth Rate. This places Amgen in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.60. Amgen's value of 7.30% is 24% below this benchmark. While the company's 10-year median is 16.10 vs. the industry median of 9.60, Amgen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.60, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current 3-Year EPS without NRI Growth Rate of 7.30% is 24% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Amgen and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current 3-Year EPS without NRI Growth Rate is 7.30%, which is 55% below median its own 10-year median of 16.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €326.28, compared to a current price of €285.00 — trading 12.7% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 7.30%, which is 55% below median its 10-year median of 16.10 and 24% below the Drug Manufacturers industry median of 9.60. Amgen's overall GF Score™ is 89/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current 3-Year EPS without NRI Growth Rate is 7.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (CHIX:AMGD) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be undervalued.
The current stock price of €285.00 is trading 12.7% below its estimated GF Value™ of €326.28.
GuruFocus considers Amgen to be Modestly Undervalued.
Key valuation signals for CHIX:AMGD:
3-Year EPS without NRI Growth Rate: 7.30% (55% below median its 10-year median of 16.10)
GF Value™: €326.28 vs. price of €285.00 (12.7% below fair value)
Industry Position: 24% below the Drug Manufacturers median (#424 of 788)
No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
89GF Score
Get the complete analysis for CHIX:AMGD
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMGD has been successfully added to your 
